SCHEMBL177458

SCHEMBL177458

CCOC(=O)c1cc2ccc(OC)cc2o1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.70
KDM4E B2RXH2 5/20 0.70
MAOB P27338 4/20 0.70
GAA P10253 4/20 0.70
ALDH1A1 P00352 4/20 0.70
GLA P06280 3/20 0.70
CA2 P00918 2/20 0.70
CA12 O43570 1/20 0.70
CA3 P07451 1/20 0.70
CA4 P22748 1/20 0.70
CA6 P23280 1/20 0.70
CA7 P43166 1/20 0.70
CA9 Q16790 1/20 0.70
CA14 Q9ULX7 1/20 0.70
CYP1A2 P05177 1/20 0.62
CYP2D6 P10635 2/20 0.56
MAPT P10636 3/20 0.55
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648621 0.89 MAOB (0.70) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL4450673 0.85 KDM4E (0.67) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL13740830 0.85 CA12 (0.57) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL18591925 0.85 CA12 (0.57) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL3626320 0.84 PTGS2 (0.58) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL28044290 0.84 CYP1A2 (0.57) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL2246104 0.84 MAPT (0.51) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL29233648 0.83 KDM4E (0.61) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL742193 0.82 MIF (0.68) HPGDKDM4EMAOBGAAALDH1A1
SCHEMBL28367859 0.82 CYP1A2 (0.50) HPGDKDM4EMAOBGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US claimed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US claimed
CN-102997991-A Ultraviolet detection device LIYANG PRODUCTIVITY PROMOTION CT 2013-03-27 CN claimed
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US disclosed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US disclosed
US-9707205-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2017-07-18 US disclosed
EP-2344484-B1 S1P RECEPTORS MODULATORS AND USE THEREOF AKAAL PHARMA PTY LTD (AU) 2016-06-08 EP disclosed
US-20160038455-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF AKAAL PHARMA PTY LTD. (AU) 2016-02-11 US disclosed
US-9193716-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2015-11-24 US disclosed
US-9181182-B2 S1P receptors modulators AKAAL PHARMA PTY LTD (AU) 2015-11-10 US disclosed
US-20150065494-A1 AMINOSTYRYLBENZOFURAN DERIVATIVES AS INHIBITORS AGAINST BETA-AMYLOID FIBRIL FORMATION, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2015-03-05 US disclosed
WO-2012068702-A1 BENZO 5-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS AND PREPARATION METHODS THEREOF 中国医学科学院医药生物技术研究所 (CN) 2012-05-31 WO disclosed
US-20120034270-A1 S1P Receptors Modulators AKAAL PHARMA PTY LTD (AU) 2012-02-09 US disclosed
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD (AU) 2011-12-29 US disclosed
EP-2344484-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF Akaal Pharma Pty Ltd (AU) 2011-07-20 EP disclosed
EP-2344446-A1 S1P RECEPTORS MODULATORS Akaal Pharma Pty Ltd (AU) 2011-07-20 EP disclosed
WO-2010043000-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF AKAAL PHARMA PTY LTD (AU) 2010-04-22 WO disclosed
WO-2010042998-A1 S1P RECEPTORS MODULATORS AKAAL PHARMA PTY LTD (AU) 2010-04-22 WO disclosed
US-7015246-B2 Benzofuran derivatives BAYER AKTIENGESELLSCHAFT (DE) 2006-03-21 US disclosed
US-20040220415-A1 Benzofuran derivatives BAYER AKTIENGESELLSCHAFT (DE) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS XPA, MEP1A, EED HPGD 2257/4885KDM4E 280/4885MAOB 4107/4885
US-20160038455-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF S1PR1, S1PR5, S1PR2 HPGD 2567/4885KDM4E 1508/4885MAOB 3603/4885
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells XPA, MEP1A, EED HPGD 2257/4885KDM4E 280/4885MAOB 4107/4885
US-20150065494-A1 AMINOSTYRYLBENZOFURAN DERIVATIVES AS INHIBITORS AGAINST BETA-AMYLOID FIBRIL FORMATION, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME APP, BACE1, APBA1 HPGD 2417/4885KDM4E 2665/4885MAOB 264/4885
US-20120034270-A1 S1P Receptors Modulators S1PR1, S1PR5, S1PR3 HPGD 2115/4885KDM4E 1701/4885MAOB 4070/4885
US-20040220415-A1 Benzofuran derivatives BPTF, ABCG2, ABCB1 HPGD 534/4885KDM4E 1659/4885MAOB 575/4885
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof S1PR1, S1PR5, S1PR2 HPGD 2567/4885KDM4E 1508/4885MAOB 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.